Biren Amin
Stock Analyst at Piper Sandler
(3.48)
# 828
Out of 5,072 analysts
66
Total ratings
54.24%
Success rate
4.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Overweight | $7 | $2.13 | +228.64% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $32.50 | +47.69% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $21.34 | -25.02% | 12 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $93 → $98 | $72.01 | +36.09% | 4 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $51 → $67 | $30.38 | +120.54% | 2 | Oct 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $21 → $31 | $12.15 | +155.14% | 2 | Oct 3, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $86.18 | +10.23% | 2 | Sep 25, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $2.83 | +112.01% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $1.13 | +253.98% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $5.43 | +213.08% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $1.46 | +379.45% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $29.08 | +30.67% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.80 | +106.90% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $36.81 | +92.88% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $11.51 | +204.22% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $18.43 | +13.98% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $72.65 | +58.29% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $21.32 | +50.13% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $4.56 | -34.21% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.44 | +4,778.05% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.90 | +5,541.59% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.49 | +337.16% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $4.74 | +617.30% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.97 | +51,654.48% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $10.69 | +30.96% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $780.19 | -11.43% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $4.28 | +133.92% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $41.65 | +142.50% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $152.16 | -54.65% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $433.61 | -64.25% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $4.11 | +3,209.00% | 4 | Mar 6, 2017 |
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $2.13
Upside: +228.64%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $32.50
Upside: +47.69%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $21.34
Upside: -25.02%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $72.01
Upside: +36.09%
LENZ Therapeutics
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $30.38
Upside: +120.54%
Ocular Therapeutix
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $12.15
Upside: +155.14%
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $86.18
Upside: +10.23%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $2.83
Upside: +112.01%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $1.13
Upside: +253.98%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $5.43
Upside: +213.08%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.46
Upside: +379.45%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $29.08
Upside: +30.67%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $5.80
Upside: +106.90%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $36.81
Upside: +92.88%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $11.51
Upside: +204.22%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $18.43
Upside: +13.98%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $72.65
Upside: +58.29%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $21.32
Upside: +50.13%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $4.56
Upside: -34.21%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.44
Upside: +4,778.05%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.90
Upside: +5,541.59%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.49
Upside: +337.16%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $4.74
Upside: +617.30%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.97
Upside: +51,654.48%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $10.69
Upside: +30.96%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $780.19
Upside: -11.43%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $4.28
Upside: +133.92%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $41.65
Upside: +142.50%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $152.16
Upside: -54.65%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $433.61
Upside: -64.25%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $4.11
Upside: +3,209.00%